J&J eyes US nod for Caplyta in bipolar mania after second trial win

More in Health

• FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

  Food and Drug Administration has issued a warning that GLP-1 drugs may pose a risk of a rare condition that causes vision loss. While the risk appears to be small and current data remains mixed, the agency wants patients to be aware of the potential complication.

  1 min read
• STAT+: GLP-1s are given an FDA warning for rare eye condition risk

  Regulatory scrutiny is expanding across widely prescribed metabolic treatments alongside significant clinical advances in genetic medicine. Biotechnology developers are moving forward with key trial milestones for severe inherited disorders, including gene-edited therapies approaching potential commercial review. These parallel events highlight both ongoing drug safety surveillance and therapeutic momentum across modern pharmaceutical pipelines.

  1 min read
• STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

  Federal regulators have cleared Bayer's novel therapy Sunharbo to prevent recurrent strokes without triggering the severe bleeding risks associated with traditional blood thinners. Concurrently, the agency issued an official warning alerting patients and physicians that popular GLP-1 treatments may cause a rare condition that leads to sudden vision loss. These actions address critical gaps in secondary stroke management while establishing new safety protocols for widely prescribed metabolic medications.

  1 min read